NewLimit, a biotech startup focused on longevity and epigenetic reprogramming, has raised $130 million in a Series B funding round, bringing its valuation to $810 million. The company was co-founded by Brian Armstrong, CEO of Coinbase. Investors in this round include Kleiner Perkins, Khosla Ventures, and Human Protocol. NewLimit aims to develop AI-powered anti-aging drugs and advance toward clinical trials. The startup's progress in extending human healthspan has reportedly moved faster than expected. This funding round highlights growing interest in biotech ventures leveraging AI and genomics for healthspan extension. Concurrently, the BIO KOREA 2025 International Convention is taking place in Seoul from May 7 to May 9, featuring participation from 24 biotech startups supported by the South Korean Ministry of SMEs and Startups. Alex Zhavoronkov, CEO of Insilico Medicine, is a keynote speaker at the event, presenting on AI-driven drug development, with his company’s candidate substance having entered phase 2 clinical trials. Other biotech developments include CRISPR Therapeutics reporting positive phase 1 trial results for CTX310 targeting ANGPTL3, which reduced bad cholesterol and triglycerides by up to 80%, and new data on the CETP inhibitor obicetrapib showing a 33% reduction in LDL cholesterol at three months in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. These advancements reflect ongoing innovation in gene editing and lipid-lowering therapies.